Reassuringly, there is no evidence that the GLP1a drugs (semaglutide, dulaglutide, exenatide, lixisenatide or liraglutide) affect the bioavailability of oral contraceptives, so no additional barrier contraception is needed whilst on these drugs
Researchers continue to explore how these mechanisms influence skin structure, wound repair, and cellular communication within connective tissues
In published preclinical research, BPC-157 has been administered at doses ranging from 6 to 50 micrograms per kilogram body weight in animal models, with most tissue-repair and gastric-protection protocols using 10 to 20 mcg/kg once or twice daily (PMID 21030672, PMID 32558293, PMID 38980576)
They will monitor your kidney function and blood sugar levels, adjusting your treatment plan as needed